skip to main content
Idioma:
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
Material Type:
Artigo 		Adicionar ao Meu Espaço

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

Sax, Paul E, Dr Prof ; Wohl, David, MD ; Yin, Michael T, Prof ; Post, Frank, MD ; DeJesus, Edwin, MD ; Saag, Michael, MD ; Pozniak, Anton, MD ; Thompson, Melanie, MD ; Podzamczer, Daniel, MD ; Molina, Jean Michel, Prof ; Oka, Shinichi, MD ; Koenig, Ellen, MD ; Trottier, Benoit, MD ; Andrade-Villanueva, Jaime, MD ; Crofoot, Gordon, MD ; Custodio, Joseph M, PharmD ; Plummer, Andrew, MS ; Zhong, Lijie, PhD ; Cao, Huyen, MD ; Martin, Hal, MD ; Callebaut, Christian, PhD ; Cheng, Andrew K, MD ; Fordyce, Marshall W, MD ; McCallister, Scott, MD

The Lancet (British edition), 2015-06, Vol.385 (9987), p.2606-2615 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
2
Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial
Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial

Cahn, Pedro, Dr ; Andrade-Villanueva, Jaime, MD ; Arribas, José R, MD ; Gatell, José M, MD ; Lama, Javier R, MD ; Norton, Michael, MD ; Patterson, Patricia, MD ; Madero, Juan Sierra, MD ; Sued, Omar, MD ; Figueroa, Maria Inés, MD ; Rolon, Maria José, MD

The Lancet infectious diseases, 2014-07, Vol.14 (7), p.572-580 [Periódico revisado por pares]

London: Elsevier Ltd

Texto completo disponível

Citações Citado por
3
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

Molina, Jean-Michel, Prof ; Andrade-Villanueva, Jaime, MD ; Echevarria, Juan, MD ; Chetchotisakd, Ploenchan, Prof ; Corral, Jorge, MD ; David, Neal, FCFP [SA] ; Moyle, Graeme, MD ; Mancini, Marco, BS ; Percival, Lisa, MS ; Yang, Rong, PhD ; Thiry, Alexandra, PhD ; McGrath, Donnie, MD

The Lancet (British edition), 2008-08, Vol.372 (9639), p.646-655 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
4
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

Cahn, Pedro, Dr ; Pozniak, Anton L, MD ; Mingrone, Horacio, MD ; Shuldyakov, Andrey, MD ; Brites, Carlos, MD ; Andrade-Villanueva, Jaime F, MD ; Richmond, Gary, MD ; Buendia, Carlos Beltran, MD ; Fourie, Jan, MD ; Ramgopal, Moti, MD ; Hagins, Debbie, MD ; Felizarta, Franco, MD ; Madruga, Jose, MD ; Reuter, Tania, MD ; Newman, Tamara, MD ; Small, Catherine B, MD ; Lombaard, John, MD ; Grinsztejn, Beatriz, MD ; Dorey, David, MMath ; Underwood, Mark, PhD ; Griffith, Sandy, PharmD ; Min, Sherene, MD

The Lancet (British edition), 2013-08, Vol.382 (9893), p.700-708 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
5
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials
Material Type:
Artigo 		Adicionar ao Meu Espaço

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

Eron, Joseph J, Prof ; Young, Benjamin, MD ; Cooper, David A, Prof ; Youle, Michael, MD ; DeJesus, Edwin, MD ; Andrade-Villanueva, Jaime, MD ; Workman, Cassy, MD ; Zajdenverg, Roberto, MD ; Fätkenheuer, Gerd, Prof ; Berger, Daniel S, MD ; Kumar, Princy N, MD ; Rodgers, Anthony J, MS ; Shaughnessy, Melissa A, MS ; Walker, Monica L, BS ; Barnard, Richard JO, PhD ; Miller, Michael D, PhD ; DiNubile, Mark J, MD ; Nguyen, Bach-Yen, MD ; Leavitt, Randi, MD ; Xu, Xia, PhD ; Sklar, Peter, Dr

The Lancet (British edition), 2010-01, Vol.375 (9712), p.396-407 [Periódico revisado por pares]

Kidlington: Elsevier Ltd

Texto completo disponível

Citações Citado por
6
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial

Eron, Joseph J, Prof ; Rockstroh, Jürgen K, MD ; Reynes, Jacques, Prof ; Andrade-Villanueva, Jaime, MD ; Ramalho-Madruga, Jose Valdez, MD ; Bekker, Linda-Gail, MD ; Young, Benjamin, MD ; Katlama, Christine, MD ; Gatell-Artigas, Jose Maria, MD ; Arribas, Jose R, MD ; Nelson, Mark, MD ; Campbell, Havilland, BS ; Zhao, Jing, PhD ; Rodgers, Anthony J, MS ; Rizk, Matthew L, PhD ; Wenning, Larissa, PhD ; Miller, Michael D, PhD ; Hazuda, Daria, PhD ; DiNubile, Mark J, MD ; Leavitt, Randi, MD ; Isaacs, Robin, MD ; Robertson, Michael N, MD ; Sklar, Peter, MD ; Nguyen, Bach-Yen, Dr

The Lancet infectious diseases, 2011-12, Vol.11 (12), p.907-915 [Periódico revisado por pares]

London: Elsevier Ltd

Texto completo disponível

Citações Citado por
7
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study

Mills, Anthony, MD ; Arribas, Jose R, MD ; Andrade-Villanueva, Jaime, Prof ; DiPerri, Giovanni, MD ; Van Lunzen, Jan, Prof ; Koenig, Ellen, MD ; Elion, Richard, MD ; Cavassini, Matthias, MD ; Madruga, Jose Valdez, MD ; Brunetta, Jason, MD ; Shamblaw, David, MD ; DeJesus, Edwin, MD ; Orkin, Chloe, MBBch ; Wohl, David A, MD ; Brar, Indira, MD ; Stephens, Jeffrey L, MD ; Girard, Pierre-Marie, Prof ; Huhn, Gregory, MD ; Plummer, Andrew, BS ; Liu, Ya-Pei, PhD ; Cheng, Andrew K, MD ; McCallister, Scott, Dr

The Lancet infectious diseases, 2016-01, Vol.16 (1), p.43-52 [Periódico revisado por pares]

United States: Elsevier Ltd

Texto completo disponível

Citações Citado por
8
Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial
Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

Cohen, Calvin J, Dr ; Andrade-Villanueva, Jaime, Prof ; Clotet, Bonaventura, MD ; Fourie, Jan, MD ; Johnson, Margaret A, Prof ; Ruxrungtham, Kiat, Prof ; Wu, Hao, MD ; Zorrilla, Carmen, MD ; Crauwels, Herta, PhD ; Rimsky, Laurence T, PhD ; Vanveggel, Simon, MSc ; Boven, Katia, MD

The Lancet (British edition), 2011-07, Vol.378 (9787), p.229-237 [Periódico revisado por pares]

Kidlington: Elsevier Ltd

Texto completo disponível

Citações Citado por
9
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study

Molina, Jean-Michel, Dr ; LaMarca, Anthony, MD ; Andrade-Villanueva, Jaime, MSc ; Clotet, Bonaventura, MD ; Clumeck, Nathan, MD ; Liu, Ya-Pei, PhD ; Zhong, Lijie, PhD ; Margot, Nicolas, MA ; Cheng, Andrew K, MD ; Chuck, Steven L, MD

The Lancet infectious diseases, 2012, Vol.12 (1), p.27-35 [Periódico revisado por pares]

London: Elsevier Ltd

Texto completo disponível

Citações Citado por
10
Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial
Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial

Lalezari, Jacob P, Dr ; Latiff, Gulam H, MD ; Brinson, Cynthia, MD ; Echevarría, Juan, MD ; Treviño-Pérez, Sandra, MD ; Bogner, Johannes R, Prof ; Thompson, Melanie, MD ; Fourie, Jan, MD ; Sussmann Pena, Otto A, MD ; Mendo Urbina, Fernando C, MD ; Martins, Marcelo, MD ; Diaconescu, Iulian G, MD ; Stock, David A, PhD ; Joshi, Samit R, DO ; Hanna, George J, MD ; Lataillade, Max, DO

The lancet HIV, 2015-10, Vol.2 (10), p.e427-e437 [Periódico revisado por pares]

Netherlands: Elsevier Ltd

Texto completo disponível

Citações Citado por

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.